Chemistry:Bersacapavir

From HandWiki

Bersacapavir is an experimental drug for the treatment of hepatitis B.[1] It prevents hepatitis B virus (HBV) from replicating by inhibiting the formation of its capsid.[2] It is also being studied for use in combination with JNJ-73763989, a small interfering RNA that targets HBV RNAs.[3]

It can be synthesized beginning with N-methylpyrrole.[4][5]

References

  1. ↑ "Bersacapavir". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800044563. 
  2. ↑ "The premise of capsid assembly modulators towards eliminating HBV persistence". Expert Opinion on Drug Discovery 18 (9): 1031–1041. 2023. doi:10.1080/17460441.2023.2239701. PMID 37477111. 
  3. ↑ "JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2". Journal of Hepatology 81 (3): 404–414. September 2024. doi:10.1016/j.jhep.2024.03.046. PMID 38583491. 
  4. ↑ "Process Development of Bersacapavir, Part 2. Early Game Route Selection: Catalytic versus Stoichiometric Haloform-Type Amidation". Organic Process Research & Development 29 (3): 624–631. 2024. doi:10.1021/acs.oprd.4c00154. 
  5. ↑ "Process Development of Bersacapavir, Part 1: Route Scouting Effort toward a Key Amide Intermediate". Organic Process Research & Development 29 (3): 616–623. 2024. doi:10.1021/acs.oprd.4c00153. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Bersacapavir&oldid=4033340"